The genetic determinants of the CYP3A5 polymorphism
Top Cited Papers
- 1 December 2001
- journal article
- research article
- Published by Wolters Kluwer Health in Pharmacogenetics
- Vol. 11 (9), 773-779
- https://doi.org/10.1097/00008571-200112000-00005
Abstract
CYP3A proteins comprise a significant portion of the hepatic cytochrome P450 (CYP) protein and they metabolize aroud 50% of drugs currently in use. The dissection of the individual contributions of the four CYP3A genes identified in humans to overall hepatic CYP3A activity has been hampered by sequence and functional similarities. We have investigated the expression of CYP3A5 and its genetic determinants in a panel of 183 Caucasian liver samples. CYP3A5 expression is increased in 10% of livers in this ethnic group. Using a high density map of CYP3A5 variants, we searched for genetic markers of the increased CYP3A5 expression. In agreement with an independent, recent study, we report that a SNP within intron 3 (g.6986G > A) is the primary cause of the CYP3A5 protein polymorphism. The frequencies of the g.6986A variant which allow for normal splicing of CYP3A5 transcripts are 5% in Caucasians, 29% in Japanese, 27% in Chinese, 30% in Koreans and 73% in African-Americans. In the last ethnic group, the expression of CYP3A5 in some individuals who carry the g.6986A variant is affected adversely by a frame shift mutation (CYP3A5*7, D348., q = 0.10). In summary, these results should add to efforts to identify clinically relevant, CYP3A5-specific reactions and to further elucidate traits responsible for variable expression of the entire CYP3A family.Keywords
This publication has 22 references indexed in Scilit:
- Cloning and Tissue Distribution of a Novel Human Cytochrome P450 of the CYP3A Subfamily, CYP3A43Biochemical and Biophysical Research Communications, 2001
- Reducing Liver Cancer--Global Control of AflatoxinScience, 1999
- Structure−Function Relationships of Human Liver Cytochromes P450 3A: Aflatoxin B1 Metabolism as a ProbeBiochemistry, 1998
- IN VITRO AND IN VIVO DRUG INTERACTIONS INVOLVING HUMAN CYP3AAnnual Review of Pharmacology and Toxicology, 1998
- Dissecting the function of cytochrome P450British Journal of Clinical Pharmacology, 1996
- Detection of a CYP3A5 Allelic Variant: A Candidate for the Polymorphic Expression of the Protein?Biochemical and Biophysical Research Communications, 1996
- Sequence of the 5′-Flanking Region of CYP3A5: Comparative Analysis with CYP3A4 and CYP3A7Biochemical and Biophysical Research Communications, 1994
- Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liverPharmacogenetics, 1994
- Absence of hepatic cytochrome P450bufI causes genetically deficient debrisoquine oxidation in manBiochemistry, 1988
- Evidence for functional and structural multiplicity of pregnenolone-16.alpha.-carbonitrile-inducible cytochrome P-450 isozymes in rat liver microsomesBiochemistry, 1987